A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Authors
Category Primary study
JournalCLINICAL CANCER RESEARCH
Year 2024
This article has no abstract
Epistemonikos ID: be74d5392a3b9f495580a046f9183d9695b532d3
First added on: Nov 23, 2025